

Paricalcitol

For use in Hemodialysis patients only	
Form	Zemplar 5 micrograms/ml solution for injection
Reconstitution	Already in solution Draw up using a 5 micron filter needle
Compatibility & Stability	N/A
Administration	IV bolus
	Zemplar solution for injection is administered via haemodialysis access
Monitoring	Important : all patients receiving pharmacological doses of vitamin D should have their plasma-calcium concentration checked at intervals as clinically indicated and whenever nausea or vomiting occur.
Adverse Drug Reactions	Dizziness may occur following administration of paricalcitol, which may have a minor influence on the ability to drive and use machines. The most common adverse reaction associated with paricalcitol therapy was hypercalcaemia, occurring in 4.7% of patients. Hypercalcaemia is dependent on the level of PTH oversuppression and can be minimised by proper dose titration.
Additional Information	Zemplar solution for injection contains 30% v/v of propylene glycol as an excipient. Isolated cases of Central Nervous System depression, haemolysis and lactic acidosis have been reported as toxic effect associated with propylene glycol administration at high doses. Although they are not expected to be found with Zemplar administration as propylene glycol is eliminated during the dialysis process, the risk of toxic effect in overdosing situations has to be taken into account. Propylene glycol interacts with heparin and neutralises its effect. Zemplar solution for injection contains propylene glycol as an excipient and should be administered through a different injection port than heparin. First dispensing on yellow Rx, subsequently sent from weekly stock order list
	sent by Dialysis Unit to Pharmacy

Information provided relates to Zemplar (AbbVie)